ORAPRED

Post-LOE

prednisolone sodium phosphate

Alcon

ANDAORALSOLUTION

Approved

Dec 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ORAPRED (prednisolone sodium phosphate) by Alcon is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Approved for the following conditions: 1, systemic lupus erythematosus, dermatomyositis (polymyositis) and 11 more indications. First approved in 2000.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many…

Worked on ORAPRED at Alcon? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ORAPRED

Mechanism of Action

Indications (14)